Literature DB >> 16766399

Ocular inflammatory responses in the EP2 and EP4 receptor knockout mice.

S Biswas1, P Bhattacherjee, C A Paterson, S L Tilley, B H Koller.   

Abstract

PURPOSE: To examine the role of EP2 and EP4 receptors in murine ocular inflammation.
METHODS: Prostaglandin EP2 and EP4 receptor knockout and wild-type mice were treated topically with prostaglandin E2, SDF-1, and RANTES and lipopolysaccharide by intravitreal injection. Paracentesis was performed by puncturing the cornea. The increase in the level of aqueous humor protein and the number of leukocytes were measured and the vascular leakage of protein was visualized using fluorescein angiography.
RESULTS: In the EP2 receptor knockout mice, there was significant inhibition of the disruption of the blood-aqueous barrier caused by lipopolysaccharides, paracentesis, prostaglandin E2, SDF-1, and RANTES. Reductions in the disruption in the blood-aqueous barrier and leukocyte infiltration after lipopolysaccharide injection and paracentesis were significant, but there was no increase in the aqueous humor protein level after prostaglandin E2 treatment in EP4 receptor knockout mice.
CONCLUSIONS: The results of the present experiments suggest that EP2 and EP4 receptors partly mediate the disruption of the blood-aqueous barrier and leukocyte infiltration induced by prostaglandin E2, SDF-1, RANTES, and lipopolysaccharides.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16766399     DOI: 10.1080/09273940600665879

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  2 in total

1.  Selective activation of the prostaglandin E2 circuit in chronic injury-induced pathologic angiogenesis.

Authors:  Elvira L Liclican; Van Nguyen; Aaron B Sullivan; Karsten Gronert
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-07-07       Impact factor: 4.799

2.  Effect of a Topical Combination of Latanoprost and Pranoprofen on Intraocular Pressure and the Ocular Surface in Open-Angle Glaucoma Patients.

Authors:  Simin Zhu; Dabo Wang; Jing Han
Journal:  J Ophthalmol       Date:  2018-12-13       Impact factor: 1.909

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.